Methods of treating splenomegaly

BTK inhibitors address the limitations of current myelofibrosis treatments by stimulating the migration of malignant CD34+ cells from the spleen, effectively reducing splenomegaly and associated complications through targeted cell trafficking and adhesion modulation.

KR1020260161638APending Publication Date: 2026-11-09TELIOS PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020267034704
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-01-08
Filing Date
2021-01-08
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Current treatments for myelofibrosis, such as ruxolitinib, are ineffective in reducing the number of malignant CD34+ cells and do not reverse fibrosis, leading to complications like splenomegaly and anemia, and are not disease-modifying.

Method used

Administering a Bruton's tyrosine kinase (BTK) inhibitor to stimulate the migration of malignant CD34+ bone marrow cells from the spleen to peripheral blood, thereby reducing splenomegaly and potentially treating associated complications like extramedullary hematopoiesis and fibrosis.

Benefits of technology

The BTK inhibitor effectively mobilizes malignant CD34+ cells, reducing splenomegaly and associated complications by modulating CXCR4-CXCL12 and VLA-4 signaling, providing a safer and more effective treatment option for myelofibrosis patients who do not respond to JAK2 inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00014_ABST
    Figure PAT00014_ABST
Patent Text Reader

Abstract

A therapeutic method and a pharmaceutical composition for treating splenomegaly in human subjects are described. In certain embodiments, the present invention comprises a therapeutic method for treating splenomegaly using a BTK inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] A method for treating splenomegaly using a Bruton's tyrosine kinase (BTK) inhibitor is disclosed herein. Background Technology

[0002] Myelofibrosis (MF) is a chronic leukemia that affects the body's blood-forming tissues. It belongs to a group of diseases called myeloproliferative disorders and is a rare type of bone marrow cancer that interferes with the normal production of blood cells. Myelofibrosis causes extensive scarring in the bone marrow, leading to severe anemia that can cause weakness and fatigue, and can also increase the risk of bleeding due to low platelet counts. Myelofibrosis often causes splenomegaly and lymph node enlargement due to the accumulation of CD34+ malignant bone marrow cells in the spleen.

[0003] The clinical spectrum of MF includes primary myelofibrosis and MF occurring during essential thrombocytopenia or polycythemia vera. Myelofibrosis is a chronic hematological malignancy characterized by splenomegaly, leukocytoblastoma, cytopenia, lacrimal polycythemia, myelofibrosis, extramedullary hematopoiesis, increased bone marrow microvascular density, and constitutive mobilization of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) expressing CD34.

[0004] Myelofibrosis is also characterized by the abnormal trafficking and homing of HSCs and HPCs in the bone marrow and peripheral blood, leading to the constitutive mobilization of HSCs and HPCs and the establishment of splenomegaly. CXCR4-CXCL12 (CXCL12 is also known as SDF-1) signaling plays a crucial role in various processes underlying proper lymphoid and myelocellular development and function, including the development and retention of progenitor cells in the bone marrow, the homing of immature and mature cells to secondary lymphoid organs, and the trafficking and homing of plasma cells to the bone marrow. In MF, the constitutive mobilization of HSCs and HPCs was associated with significant alterations in the CXCR4-CXCL12 axis, which arises from the downregulation of CXCR4 expression by myelofibrotic CD34+ cells due to hypermethylation of the CXCR4 promoter and the proteolytic degradation of CXCL12. In the spleen of MF patients, CXCL12 and integrins, such as Very Late Antigen-4 (VLA-4), are highly expressed, and CXCL12 acts as a chemoattractor for mobilized CD34+ cells. This contrasts with bone marrow and peripheral blood, where CXCL12 expression levels are abnormally low. Adhesion molecules attracted to the spleen via CXCL12, such as VLA-4 and its ligand VCAM-1 (vascular cell adhesion molecule 1), sequester CD34+ cells, leading to splenomegaly. Furthermore, these abnormal stem cell behaviors can be influenced not only by the intrinsic characteristics of stem cells but also by regulatory signals provided by the MF microenvironment (Wang (2015) Experimental Hematology 43, 100-109). Therefore, the ability to manipulate cell trafficking, homing, and sequestration through these pathways represents an opportunity to treat MF patients.

[0005] Bruton's tyrosine kinase is a non-receptor tyrosine kinase belonging to the Tec family and plays an important role in various benign and malignant cells of the hematopoietic system. Furthermore, recent clinical studies using the irreversible oral BTK inhibitors acalabrutinib and ibrutinib have demonstrated excellent clinical activity and tolerability against various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia, and diffuse large B-cell lymphoma. Moreover, it is now evident that the mechanism of action of BTK inhibitors is multifactorial, with significant components of their function in lymphocytic malignancies involving the disruption of tumor cells and their protective microenvironment. Inhibition of BTK has been shown to regulate CLL, MCL, and malignant myeloid cell migration in acute myeloid leukemia by inhibiting CXCR4-CXCL12-induced cell trafficking, homing, and integrin attachment through the downregulation of the expression of multiple vascular adhesion molecules (Zaitseva (2014) Oncotarget 5, 9930-9938). CXCL12 plays a pivotal role in the pathogenesis and progression of CLL by inducing cell survival and proliferation through the regulation of CLL cell interactions with the stromal microenvironment. BTK plays a role in signaling activated by the CXCR4-CXCL12 signaling axis and is involved in rapid integrin activation. Inhibition of BTK prevents CXCL12-induced triggering of lymphocyte function-associated antigen-1 (LFA-1) and VLA-4 integrins. Additionally, BTK inhibition controls integrin affinity by blocking the activation of the small GTP-binding protein RhoA. Importantly, BTK tyr-phosphorylation and activation by CXCL12 depend on the upstream activation of JAK2 (Janus kinase 2).Therefore, BTK and JAK protein tyrosine kinases exhibit hierarchical activity in both chemokine and integrin activation and cell adhesion dependent on these factors (Montresor (2018) Oncotarget, 9, 35123-35140). Finally, BTK is highly expressed in both mature and primitive myeloid cells, including HSCs and HPCs. The CXCR4-CXCL12 signaling axis is an important means of mobilization and homing for CD34+ cells.

[0006] Currently, ruxolitinib, fedratinib, and allogeneic stem cell transplantation are the primary means of treating patients with MF. Ruxolitinib, a drug developed to inhibit JAK2 mutations, is often used as a first-line treatment. It is also effective in individuals with CALR (caleticulin, located on chromosome 19pl3.2) or MPL (myeloproliferative leukemia virus oncogene; located on chromosome lp34) mutations, as they also activate JAK2. While effective in reducing spleen size and controlling symptoms, and potentially increasing overall survival, it does not reverse fibrosis in most cases and can lead to anemia and low platelet counts. Surprisingly, ruxolitinib acts equally effectively in reducing splenomegaly and controlling symptoms in MF patients lacking the JAK2V617 driver mutation, which confuses initial treatment expectations. However, ruxolitinib is not disease-modifying because it is ineffective in reducing the number of malignant CD34+ cells or the burden of the Jak allele. Nevertheless, due to a better understanding of the cellular and molecular events leading to the development of MF, there is potential for safer and more effective targeted therapies, such as BTK inhibitors, to treat myeloproliferative neoplasms with splenomegaly through the coordination of cell trafficking, homing, and adhesion. The problem to be solved

[0007] ** means of solving the problem

[0008] The present invention relates to a method for treating splenomegaly in a human subject requiring treatment for splenomegaly, comprising administering a Bruton tyrosine kinase inhibitor to said human subject. In some embodiments, the human subject has an accumulation of malignant CD34+ bone marrow cells in the spleen. In some embodiments, the malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells. In some embodiments, the human subject suffers from myelofibrosis. In some embodiments, the myelofibrosis is selected from the group consisting of primary myelofibrosis (PMF), post-PV myelofibrosis (post-PV-MF), and post-ET myelofibrosis (post-ET-MF). In some embodiments, the human subject did not respond to ruxolitinib therapy. In some embodiments, the human subject has a JAK2V617F mutation and optionally has acute myeloid leukemia (AML) secondary to a myeloproliferative neoplasm (MPN). In some embodiments, human subjects do not have the JAK2V617F mutation and optionally have acute myeloid leukemia secondary to a myeloproliferative neoplasm.

[0009] In some embodiments, a BTK inhibitor is administered in an amount sufficient to stimulate the migration of malignant CD34+ bone marrow cells into the peripheral blood of a human subject. In some embodiments, a BTK inhibitor is administered in an amount sufficient to stimulate the apoptosis of malignant CD34+ bone marrow cells in the spleen of a human subject. In some embodiments, a BTK inhibitor is administered in an amount sufficient to reduce the activity of VLA-4 in malignant CD34+ bone marrow cells. In some embodiments, a BTK inhibitor is administered in an amount sufficient to reduce the expression of VLA-4 in malignant CD34+ bone marrow cells.

[0010] The present invention also relates to a method for stimulating the migration of malignant CD34+ bone marrow cells from the spleen to peripheral blood in a human subject suffering from splenomegaly, comprising administering a BTK inhibitor to a human subject suffering from splenomegaly. In some embodiments, the human subject has an accumulation of malignant CD34+ bone marrow cells in the spleen. In some embodiments, the method comprises stimulating the apoptosis of malignant CD34+ bone marrow cells in the spleen by administering a BTK inhibitor. In some embodiments, the malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells. In some embodiments, the human subject suffers from myelofibrosis. In some embodiments, the myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In some embodiments, the human subject did not respond to ruxolitinib therapy. In some embodiments, the human subject has the JAK2V617F mutation and optionally has acute myeloid leukemia secondary to a myeloproliferative neoplasm. In some embodiments, the human subject does not have the JAK2V617F mutation and optionally has acute myeloid leukemia secondary to a myeloproliferative neoplasm.

[0011] The method of the present invention encompasses the treatment of human subjects who have not been treated with JAK2 inhibitors. The method of the present invention also encompasses the treatment of human subjects who are intolerant to JAK2 inhibitors. The method of the present invention encompasses the treatment of human subjects who are unfit for treatment with JAK2 inhibitors. The method of the present invention encompasses the treatment of human subjects who relapse after treatment with JAK2 inhibitors or who are refractory to treatment with JAK2 inhibitors.

[0012] In the method of the present invention, the BTK inhibitor is administered once daily at a dose selected from the group consisting of 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, 480 mg, and 560 mg.

[0013] In the method of the present invention, the BTK inhibitor is administered twice daily at a dose selected from the group consisting of 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, 480 mg, and 560 mg.

[0014] In the method of the present invention, the BTK inhibitor is administered orally.

[0015] In the method of the present invention, the BTK inhibitor is a covalent BTK inhibitor.

[0016] In the method of the present invention, the BTK inhibitor is a non-covalent BTK inhibitor. Effects of the invention

[0017] ** Brief explanation of the drawing

[0018] Figures 1a and 1b are graphs showing the inhibition of cell migration to SDF-1. Figure 2 is a graph showing the release of cells from fibronectin. Figure 3 is a graph showing the levels of cell surface molecules. Figure 4 is a graph showing cytokine and chemokine levels. Specific details for implementing the invention

[0019] Although preferred embodiments of the present invention are presented and described herein, such embodiments are provided merely as examples and are not intended to otherwise limit the scope of the invention. Various alternatives to the described embodiments of the present invention may be used to practice the invention.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention pertains.

[0021] As used herein, the terms “administered in combination” and “co-administration” encompass the administration of two or more active pharmaceutical ingredients to a subject such that both the agent and / or its metabolite are simultaneously present in the subject. Co-administration includes simultaneous administration of individual compositions, administration of individual compositions at different times, or administration of a composition containing two or more agents.

[0022] The terms “effective dose,” “therapeutic effective dose,” or “sufficient amount” refer to an amount of the active pharmaceutical ingredient or combination of active pharmaceutical ingredients as described herein that is sufficient to carry out an intended application, including but not limited to the treatment of a disease. The therapeutic effective dose may vary depending on the intended application (in vitro or in vivo), the subject and disease state to be treated (e.g., subject’s body weight, age, and sex), the severity of the disease state, the mode of administration, and other factors that can be readily determined by a person skilled in the art. The above terms also apply to a dose that induces a specific response in target cells (e.g., malignant CD34+ bone marrow cells). The specific dose will vary depending on the specific compound selected, the subsequent administration regimen, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to be administered, and the physical delivery system carrying the compound.

[0023] "Myelofibrosis" refers to spontaneous scarring (fibrosis) of the bone marrow that interferes with the normal production of blood cells, causing severe anemia and enlargement of the spleen, lymph nodes, and liver. It may be associated with various diseases, primarily myeloproliferative (preleukemic) disorders. It is also known as myelometaplasia of unknown etiology. As used herein, myelofibrosis includes, but is not limited to, primary myelofibrosis, myelofibrosis following polycythemia vera, and myelofibrosis following thrombocytopenia. As used herein, myelofibrosis is characterized by the accumulation of malignant CD34+ bone marrow cells in the bone marrow, spleen, and lymph nodes.

[0024] "Pharmaceutical acceptable carriers" or "pharmaceutical acceptable excipients" are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption retardants. The use of such media and agents for active pharmaceutical ingredients is widely known in the relevant art. Any conventional media or agent is considered for use in the therapeutic compositions of the present invention, except where it is incompatible with the active pharmaceutical ingredient. Additional active ingredients may also be incorporated into the described compositions.

[0025] The term "pharmaceutical acceptable salt" refers to a salt derived from various organic and inorganic counterions that are widely known in the relevant art. Pharmaceutically acceptable acid addition salts may be formed using inorganic and organic acids. Inorganic acids from which salts may be derived include, for example, hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts may be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvate, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Pharmaceutically acceptable base addition salts may be formed using inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins. Specific examples include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In selected embodiments, pharmaceutically acceptable base addition salts are selected from ammonium, potassium, sodium, calcium, and magnesium salts. The term "cocrystal" refers to a molecular complex derived from a number of cocrystallizing agents known in the art. Unlike salts, cocrystals typically do not involve proton transfer between the cocrystal and the drug, but instead involve intermolecular interactions between the cocrystallizing agent and the drug within the crystal structure, such as hydrogen bonding, aromatic ring stacking, or dispersion forces.

[0026] The term "QD," "qd," or "qd" means once a day (quaque die), once a day, or once every day. The term "BID," "bid," or "bid" means twice a day (bis in die), twice a day, or twice every day. The term "TID," "tid," or "tid" means three times a day (ter in die), three times a day, or three times every day. The term "QID," "qid," or "qid" means four times a day (quater in die), four times a day, or four times every day.

[0027] As used herein, the term "splenomegaly" refers to the enlargement of the spleen as measured by size or weight. In some embodiments, the enlargement is due to the isolation of malignant CD34+ bone marrow cells and the resulting extramedullary hematopoiesis.

[0028] As used herein, the term "therapeutic effect" encompasses therapeutic benefits and / or preventive benefits as described above. Preventive effects include the delay or elimination of the onset of a disease or condition, the delay or elimination of the onset of symptoms of a disease or condition, the delay, cessation, or reversal of the progression of a disease or condition, or any combination thereof.

[0029] For example, where a range is used herein to describe physical or chemical properties, such as molecular weight or chemical formula, it is intended to include all combinations and subcombinations of the range and specific embodiments therein. When referring to a number or numerical range, the use of the term “about” implies that the mentioned number or numerical range is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary, for example, from 1% to 15% of the mentioned number or numerical range. The term “comprising” (and related terms, e.g., “comprising,” “comprising,” “having,” or “comprising”) includes embodiments of any material composition, method, or process that are “consisted of” or “essentially composed of” the features described, for example.

[0030] The BTK inhibitor compounds of the present invention also include crystalline and amorphous forms of any of the compounds in Table 1, including, for example, polymorphs, pseudo-polymorphs, solvates, hydrates, non-solvent polymorphs (including anhydrides), stereomorphs and amorphous forms of the compounds, as well as mixtures thereof. "Crystalline form" and "polymorph" are intended to include all crystalline and amorphous forms of the compounds, including, for example, polymorphs, pseudo-polymorphs, solvates, hydrates, non-solvent polymorphs (including anhydrides), stereomorphs and amorphous forms, as well as mixtures thereof, unless a specific crystalline or amorphous form is mentioned.

[0031] How to treat complications of myelofibrosis

[0032] The present disclosure relates to the discovery that BTK inhibitors can be used to treat various complications of myelofibrosis, including, for example, splenomegaly, extramedullary hematopoiesis, and fibrosis. Accordingly, in a particular aspect, the present disclosure relates to a method for treating splenomegaly, extramedullary hematopoiesis, and fibrosis in a human subject requiring treatment for splenomegaly, by administering an effective amount of a BTK inhibitor in combination with one or more other supportive therapies or activators for treating splenomegaly. The present disclosure demonstrates that a preferred therapeutic agent can be selected based on BTK inhibition. Therefore, although we do not wish to be bound by a specific mechanism of action, BTK inhibition modulates one or more downstream signaling components (e.g., CXCR-4, CXCL12, VLA-4, VCAM-1) to mobilize the migration of CD34+ cells into peripheral blood, and is expected to be useful for the treatment or prevention of complications associated with myelofibrosis, particularly one or more complications of myelofibrosis including but not limited to splenomegaly, extramedullary hematopoiesis, and fibrosis.

[0033] Accordingly, the present invention relates to a method for treating splenomegaly, comprising the step of administering a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof to a human requiring treatment for splenomegaly. In some embodiments, splenomegaly is secondary to myelofibrosis. In some embodiments, MF is primary myelofibrosis, also known as chronic idiopathic myelofibrosis (cIMF). This is in contrast to myelofibrosis occurring secondary to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention encompasses treating splenomegaly caused by myelofibrosis occurring secondary to polycythemia vera or essential thrombocytopenia. In some embodiments, the BTK inhibitor is any of the compounds in Table 1 or a pharmaceutically acceptable salt thereof.

[0034] The present invention also relates to a method for treating splenomegaly, comprising the step of administering a BTK inhibitor or a pharmaceutically acceptable salt thereof to a human requiring treatment for splenomegaly. In one embodiment, splenomegaly is present in a human subject suffering from myelofibrosis selected from the group consisting of primary myelofibrosis, secondary myelofibrosis, myelofibrosis secondary to polycythemia vera (PV), myelofibrosis secondary to essential thrombocytopenia (ET), myelofibrosis secondary to chronic myeloid leukemia (CML), and idiopathic myelofibrosis. In one embodiment, the myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF. In one embodiment, the human is determined to be hydroxyurea (HU) intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea tolerance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent.

[0035] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any myeloproliferative neoplasm in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of reduction in the severity or progression of any myelofibrosis in human subjects receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in human subjects after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt.

[0036] In one embodiment, the present invention relates to a method for treating splenomegaly in a human, comprising the step of administering to the human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0037] In one embodiment, the present invention relates to a method for treating extramedullary hematopoiesis in a human, comprising the step of administering to the human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0038] In one embodiment, the present invention relates to a method for treating fibrosis in a human, comprising the step of administering to the human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from any of Table 1, or a pharmaceutically acceptable salt thereof.

[0039] In one embodiment, a human subject has an accumulation of malignant CD34+ bone marrow cells in his spleen. These malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells. In one embodiment, a BTK inhibitor is administered at a therapeutically effective amount sufficient to stimulate the migration of malignant CD34+ bone marrow cells into the peripheral blood of the human subject. In one embodiment, a BTK inhibitor is administered at a amount sufficient to inactivate VLA-4 in malignant CD34+ bone marrow cells.

[0040] In one embodiment, the present invention relates to a method for stimulating the migration of malignant CD34+ bone marrow cells from the spleen to peripheral blood in a human subject suffering from myelofibrosis, comprising administering a BTK inhibitor to said human subject. In one embodiment, the BTK inhibitor is administered in an amount sufficient to reduce the chemoattracting effect of these molecules on malignant CD34+ bone marrow cells by reducing the activity of CXCR4 and CXCL12. The reduction in CXCR4 and CXCL12 activity contributes to the sequestration of malignant myeloid CD34+ cells in the spleen. In one embodiment, the human subject has an accumulation of malignant CD34+ bone marrow cells in his spleen. These malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells.

[0041] In one embodiment, the method encompasses treating complications associated with myelofibrosis, such as splenomegaly, extramedullary hematopoiesis, and fibrosis, but not treating myelofibrosis itself (e.g., only complications of myelofibrosis are treated in humans and myelofibrosis is not treated).

[0042] In one embodiment, the BTK inhibitor is 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 560 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg BID, 90 mg BID, 100 It is administered at a dosage selected from the group consisting of mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID. In one embodiment, the BTK inhibitor is administered to humans according to the section dosage and administration regimen.

[0043] In one embodiment, a human having splenomegaly, extramedullary hematopoiesis, or fibrosis has myelofibrosis characterized by the presence of a CALR mutation (caleticulin, located on chromosome 19pl3.2) in a human subject as described in the literature [Massie, New Engl. J. Med. (2013) 25, 2379-2390] (the full text of which is incorporated herein by reference).

[0044] In one embodiment, a human having splenomegaly, extramedullary hematopoiesis, or fibrosis has myelofibrosis characterized by the presence of an MPL mutation (myeloproliferative leukemia virus oncogene; located on chromosome lp34) in a human subject as described in the literature [Pikman, Plos Med. (2006) 3, e270] (the full text of which is incorporated herein by reference).

[0045] In one embodiment, a human suffering from splenomegaly, extramedullary hematopoiesis, or fibrosis has myelofibrosis characterized by a JAK2V617F mutation in the human subject. JAK2V617F is a functional mutation that promotes cytokine-independent growth of bone marrow cells, as described in the literature [Nakatake (Oncogene (2012) 31, 1323-1333)] (the full text of which is incorporated herein by reference).

[0046] In one embodiment, a human suffering from splenomegaly, extramedullary hematopoiesis, or fibrosis has myelofibrosis characterized by one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR, and combinations thereof.

[0047] In one embodiment, a human suffering from splenomegaly, extramedullary hematopoiesis, or fibrosis has myelofibrosis characterized by the absence of a JAK2V617F mutation.

[0048] In one embodiment, the present invention relates to a method for treating splenomegaly in a human subject, comprising the step of administering a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof, to a human subject suffering from myelofibrosis secondary to essential thrombocytopenia in said human subject.

[0049] In one embodiment, the present invention relates to a method for treating myelofibrosis secondary to chronic myeloid leukemia in a human, comprising the step of administering to a human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0050] Table 1: BTK inhibitors

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059]

[0060] In some embodiments, the BTK inhibitor is TG-1701 or Loxo-305.

[0061] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID. In one embodiment, MF is selected from the group consisting of myelofibrosis, primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0062] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID, wherein MF is selected from the group consisting of MF secondary to polycythemia vera, MF secondary to essential thrombocytopenia, and MF secondary to CML.

[0063] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating primary myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0064] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis after polycythemia vera in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0065] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis after essential thrombocytopenia in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0066] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the MF is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0067] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating primary myelofibrosis, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof.

[0068] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis after polycythemia vera, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0069] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis after essential thrombocytopenia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0070] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to polycythemia vera, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof.

[0071] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to essential thrombocytopenia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0072] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to chronic myeloid leukemia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0073] In one embodiment, the present invention relates to the use of a composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis, comprising the step of administering to a human one or more doses of a composition comprising a BTK inhibitor selected from Table 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis following polycythemia vera, and myelofibrosis following thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0074] The method described above may be used as a first-line cancer therapy, or after treatment with a conventional regimen including ruxolitinib or fedratinib.

[0075] BTK inhibitors or pharmaceutically acceptable salts thereof may also be used in combination with radiation therapy, hormone therapy, surgery, and immunotherapy, which are therapies widely known to those skilled in the art, for treating myelofibrosis selected from the group consisting of primary myelofibrosis, idiopathic myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0076] Mechanism of action

[0077] Myelofibrosis is characterized by the constitutive mobilization of hematopoietic stem cells and progenitor cells and the establishment of extramedullary hematopoiesis (EMFI). Both splenic and peripheral blood myelofibrosis CD34+ cells share the same defect in the ability to return to the bone marrow but not to the spleen. This trafficking pattern cannot be attributed to the mismatched expression of integrins or chemokine receptors, other than the down-regulation of CXCR4 by both peripheral blood and splenic CD34+ cells. The concentration of the intact chemoattractant CXCL12 (a ligand for CXCR4) is higher in splenic myelofibrosis plasma than in peripheral blood myelofibrosis plasma. Functionally inactive, truncated products of CXCL12, which are products of proteolytic degradation by serine proteases, were detected at similar levels in both splenic and peripheral blood myelofibrosis plasma. The myelofibrotic splenic microenvironment is characterized by increased levels of intact functional CXCL12 that contribute to the localization of malignant CD34+ bone marrow cells into the spleen (Wang (2015) Exp. Hematol. 43, 100-109).

[0078] Abnormal CD34+ cell trafficking and extramedullary hematopoiesis are essential components of the pathology of myelofibrosis. The constitutive mobilization of malignant myeloid CD34+ cells is explained by the downregulation of CXCR4 on these cells and a decrease in the amount of intact CXCL12, which acts as a chemoattractor for CD34+ cells. Increased concentrations of intact, fully functional CXCL12 within the spleen of myelofibrosis contribute to the homing of malignant myeloid CD34+ cells to the spleen rather than the bone marrow in patients with myelofibrosis, ultimately leading to extramedullary hematopoiesis in the spleen. The initial establishment of extramedullary hematopoiesis in patients with myelofibrosis is partly due to the presence of intact CXCL12 in the normal spleen, and its production is localized to the cells lining the blood vessels. As myelofibrosis progresses, CD34+ cells are progressively depleted in the bone marrow, but CD34+ cells remain in the peripheral blood, which is a result of CD34+ cell trafficking between the myelofibrotic spleen, peripheral blood, and bone marrow (Wang (2015) Exp. Flematol. 43, 100-109).

[0079] Disease progression in myelofibrosis is frequently accompanied by greater splenomegaly due to increased extramedullary hematopoiesis. For EMH to occur, a permissive microenvironment must be established that supplies the signals necessary for myelofibrotic hematopoietic stem cells to enter the spleen and initiate and sustain hematopoiesis. Alterations within the splenic microenvironment contribute to the abnormal trafficking of myelofibrotic stem cells (MF-SCs), leading to the development of EMFI. Splenic myelofibrosis plasma is characterized by increased concentrations of CXCL12, which triggers the initiation and development of EMFI in patients with myelofibrosis. The splenic cells responsible for the overproduction of CXCL12 appear to be endothelial cells. The microenvironments within the bone marrow and spleen differ in myelofibrosis, partly due to the increased levels of intact CXCL12 present in the spleen. These different microenvironments within the bone marrow and spleen contribute to the segregation of malignant CD34+ bone marrow cells in the spleen and subsequent disease progression (Wang (2015) Exp. Flematol. 43, 100-109).

[0080] Reduced CXCR4 in peripheral blood and bone marrow releases malignant CD34+ cells from the bone marrow, while high CXCL12 levels attract malignant CD34+ bone marrow cells to the spleen, and low levels of CXCL12 in peripheral blood promote sequestration in the spleen. This leads to the accumulation of malignant CD34+ bone marrow cells in the spleen and depletes CD34+ bone marrow cells from the bone marrow. Inhibition of BTK reduces the expression and activity of CXCL12, thereby reducing the chemoattractant effect of CXCL12 that causes the accumulation of malignant CD34+ bone marrow cells in the spleen. This inhibition of CXCL12 in the spleen causes malignant CD34+ bone marrow cells to migrate from the spleen to the peripheral blood, effectively reducing the formation of myelofibrotic tissue in the spleen.

[0081] The concentration of soluble VCAM-1, a degradation product of VCAM-1, is elevated in the plasma of patients with primary myelofibrosis and correlates with the absolute number of CD34+ cells in the peripheral blood of patients with primary myelofibrosis. Additionally, CXCR-4 expression by CD34+ cells is downregulated, and plasma CXCL12 levels are elevated, which explains the altered CLCL12 / CXCR-4 interaction leading to CD34+ cell mobilization. The constitutive mobilization of myelofibrotic FISCs and FHPCs was associated with significant alterations in the CXCR4 / CXCL12 axis, which occurs as a result of the downregulation of CXCR4 expression by myelofibrotic CD34+ cells due to hypermethylation of the CXCR4 promoter and the proteolytic degradation of CXCL12 and vascular adhesion molecule-1 (VCAM-1). Drugs targeting proteases responsible for constitutive CD34+ cell mobilization offer an interesting strategy to disrupt or eliminate the establishment of extramedullary hematopoietic sites in patients with primary myelofibrosis.

[0082] The migration of leukocytes and progenitor cells is important for the process of extramedullary hematopoiesis. As mentioned above, this process is regulated by chemokines such as CXCL12 and also mediated by integrins LFA1 and VLA4. JAKV617F (but without CALR mutation) stimulates integrin signaling through the activation of the small GTPase Rap1, thereby increasing granulocyte binding to ICAM-1 and VCAM-1 (abundantly expressed in the spleen). Differences in chemotaxis, along with differential integrin binding between JAKV617F and CALR-mutated leukocytes, may contribute to extramedullary hematopoiesis. In primary myelofibrosis, the risk of splenomegaly is less pronounced in CALR-mutated patients than in JAKV617F-positive individuals. The JAK2V617F kinase cooperates with the chemokine CXCL12 through its signaling intermediates BTK, PI3K / AKT, PLCy1, and RhoA to regulate cell migration. This mechanism provides the basis for the contribution of these downstream molecules to the abnormal cell migration of stem cells and JAKV617F-positive myeloid progenitor cells migrating from the bone marrow to peripheral blood and to extramedullary organs. Accordingly, the use of BTK inhibitors to inhibit the abnormal migration and homing of JAKV617F-positive clones in the MPN is included in the present invention. However, in some embodiments, the presence of JAKV617F-positive clones does not affect treatment with BTK inhibitors. Therefore, both BTK inhibitor treatment of human subjects with JAKV617F mutations and human subjects without JAKV617F mutations are included in the present invention.

[0083] How to treat myelofibrosis

[0084] The present invention relates to a method for treating myelofibrosis, comprising the step of administering a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof to a human requiring treatment for myelofibrosis. In some embodiments, MF is primary myelofibrosis, also known as chronic idiopathic myelofibrosis. This is in contrast to myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention encompasses treating myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. In some embodiments, the BTK inhibitor is any compound of Table 1 or a pharmaceutically acceptable salt thereof.

[0085] The present invention also relates to a method for treating myelofibrosis, comprising the step of administering a BTK inhibitor or a pharmaceutically acceptable salt thereof to a human requiring treatment for myelofibrosis. In one embodiment, the myelofibrosis is selected from the group consisting of primary myelofibrosis, secondary myelofibrosis, myelofibrosis secondary to polycythemia vera, myelofibrosis secondary to essential thrombocytopenia, myelofibrosis secondary to chronic myeloid leukemia, and idiopathic myelofibrosis. In one embodiment, the myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to have hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent.

[0086] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of reduction in the severity or progression of any myelofibrosis in human subjects receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in human subjects after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt.

[0087] In one embodiment, the present invention relates to a method for treating primary myelofibrosis in a human, comprising the step of administering to a human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the BTK inhibitor is a covalent or irreversible BTK inhibitor. In some embodiments, the BTK inhibitor is a non-covalent or reversible BTK inhibitor.

[0088] In one embodiment, the present invention relates to a method for treating myelofibrosis after polycythemia vera in a human, comprising the step of administering to the human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0089] In one embodiment, the present invention relates to a method for treating myelofibrosis after essential thrombocytopenia in a human, comprising the step of administering to the human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from any of Table 1, or a pharmaceutically acceptable salt thereof.

[0090] In one embodiment, a human subject has an accumulation of malignant CD34+ bone marrow cells in his spleen. These malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells. In one embodiment, a BTK inhibitor is administered at a therapeutically effective amount sufficient to stimulate the migration of malignant CD34+ bone marrow cells from the bone marrow or spleen of the human subject into the peripheral blood. In one embodiment, a BTK inhibitor is administered at a amount sufficient to inactivate VLA-4 in malignant CD34+ bone marrow cells.

[0091] In one embodiment, the present invention relates to a method for stimulating the migration of malignant CD34+ bone marrow cells from the spleen to peripheral blood in a human subject suffering from myelofibrosis, comprising administering a BTK inhibitor to said human subject. In one embodiment, the human subject has an accumulation of malignant CD34+ bone marrow cells in his spleen. These malignant CD34+ bone marrow cells have reduced CXCR4 expression compared to normal bone marrow cells.

[0092] In one embodiment, the present invention relates to a method for treating secondary myelofibrosis, comprising the step of administering a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof, to a human requiring treatment for secondary myelofibrosis, wherein the secondary myelofibrosis is selected from the group consisting of myelofibrosis secondary to polycythemia vera and myelofibrosis secondary to essential thrombocytopenia. In one embodiment, polycythemia vera is phlebolysis-dependent polycythemia vera. In one embodiment, the human subject is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human has splenomegaly and is phlebolysis-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebolysis-dependent. In one embodiment, a human subject failed prior MF therapy with ruxolitinib or fedratinib.

[0093] In one embodiment, the BTK inhibitor is 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 560 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg BID, 90 mg BID, 100 It is administered at a dosage selected from the group consisting of mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID. In one embodiment, the BTK inhibitor is administered to humans according to the section dosage and administration regimen.

[0094] In one embodiment, the myelofibrosis is selected from primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocytopenia. In one embodiment, the myelofibrosis is selected from primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocytopenia, and the human subject failed ruxolitinib or fedratinib therapy for PMF, post-PV-MF or post-ET-MF.

[0095] In one embodiment, myelofibrosis is characterized by the presence of a CALR mutation.

[0096] In one embodiment, myelofibrosis is characterized by the presence of an MPL mutation.

[0097] In one embodiment, myelofibrosis is characterized by a JAK2V617F mutation in a human subject.

[0098] In one embodiment, myelofibrosis is characterized by one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR and combinations thereof.

[0099] In one embodiment, the present invention relates to a method for treating myelofibrosis secondary to polycythemia vera in a human, comprising the step of administering to a human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0100] In one embodiment, the present invention relates to a method for treating myelofibrosis secondary to essential thrombocytopenia in a human, comprising the step of administering to a human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0101] In one embodiment, the present invention relates to a method for treating myelofibrosis secondary to chronic myeloid leukemia in a human, comprising the step of administering to a human a therapeutically effective amount of a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

[0102] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID. In one embodiment, MF is selected from the group consisting of myelofibrosis, primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0103] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID, wherein MF is selected from the group consisting of MF secondary to polycythemia vera, MF secondary to essential thrombocytopenia, and MF secondary to CML.

[0104] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating primary myelofibrosis in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0105] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis after polycythemia vera in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0106] In one embodiment, the present invention provides a therapeutically effective amount to a human of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, 15 mg QD, 25 mg QD, 30 mg QD, 50 mg QD, 60 mg QD, 75 mg QD, 90 mg QD, 100 mg QD, 120 mg QD, 150 mg QD, 175 mg QD, 180 mg QD, 200 mg QD, 225 mg QD, 240 mg QD, 250 mg QD, 275 mg QD, 300 mg QD, 325 mg QD, 350 mg QD, 360 mg QD, 375 mg QD, 480 mg QD, 15 mg BID, 25 mg BID, 30 mg BID, 50 mg BID, 60 mg BID, 75 mg The present invention relates to a method for treating myelofibrosis after essential thrombocytopenia in humans, comprising the step of administering a dosage selected from the group consisting of BID, 90 mg BID, 100 mg BID, 120 mg BID, 150 mg BID, 175 mg BID, 180 mg BID, 200 mg BID, 225 mg BID, 240 mg BID, 250 mg BID, 275 mg BID, 300 mg BID, 325 mg BID, 350 mg BID, 360 mg BID, 375 mg BID, and 480 mg BID.

[0107] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the MF is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0108] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating primary myelofibrosis, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof.

[0109] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis after polycythemia vera, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0110] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis after essential thrombocytopenia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0111] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to polycythemia vera, comprising the step of administering to a human one or more doses of a BTK inhibitor compound from Table 1 or a pharmaceutically acceptable salt thereof.

[0112] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to essential thrombocytopenia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0113] In one embodiment, the present invention relates to the use of a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis secondary to chronic myeloid leukemia, comprising the step of administering to a human one or more doses of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[0114] In one embodiment, the present invention relates to the use of a composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating myelofibrosis, comprising the step of administering to a human one or more doses of a composition comprising a BTK inhibitor selected from Table 1 or a pharmaceutically acceptable salt thereof. In one embodiment, the myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis following polycythemia vera, and myelofibrosis following thrombocytopenia. In one embodiment, the primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0115] The method described above may be used as a first-line cancer therapy, or after treatment with a conventional regimen including ruxolitinib or fedratinib.

[0116] BTK inhibitors or pharmaceutically acceptable salts thereof may also be used in combination with radiation therapy, hormone therapy, surgery, and immunotherapy, which are therapies widely known to those skilled in the art, for treating myelofibrosis selected from the group consisting of primary myelofibrosis, idiopathic myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia. In one embodiment, primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF.

[0117] Treatment methods for myeloproliferative neoplasms

[0118] The present invention also relates to a method for treating MPN, comprising the step of administering a BTK inhibitor or a pharmaceutically acceptable salt thereof to a human who requires treatment for MPN. In one embodiment, MPN is selected from the group consisting of polycythemia vera, myelofibrosis, primary myelofibrosis, thrombocytopenia, essential thrombocytopenia, idiopathic systemic mastocytosis (SM), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia not otherwise specified (CEL-NOS), unclassified myeloproliferative neoplasm (MPN-U), myelodysplastic syndrome (MDS), and systemic mastocytosis (SMCD). In one embodiment, MPN is selected from the group consisting of chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia, chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), pediatric myelomonocytic leukemia (JMML), hypereosinophilic syndrome (HES), and myelodysplastic / myeloproliferative neoplasm with ring sideroblastosis and thrombocytopenia (MDS / MPN-RS-T). In one embodiment, polycythemia vera is phlebectomy-dependent polycythemia vera. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistant (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebectomy-dependent. In one embodiment, the human subject is splenomegaly-free and venostole-dependent.

[0119] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of reduction in the severity or progression of any myelofibrosis in human subjects receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in human subjects after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt.

[0120] In one embodiment, the present invention relates to a method for treating MPN, comprising the step of administering a BTK inhibitor, which is a compound selected from Table 1, or a pharmaceutically acceptable salt thereof, to a human requiring treatment for MPN, wherein MPN is selected from the group consisting of polycythemia vera and essential thrombocythemia. In one embodiment, polycythemia vera is phlebolysis-dependent polycythemia vera. In one embodiment, the human subject is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human has splenomegaly and is phlebolysis-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebolysis-dependent. In one embodiment, the human subject failed prior MPN therapy with ruxolitinib or fedratinib.

[0121] The present invention also relates to a method for treating blast phase MPN, comprising the step of administering a BTK inhibitor or a pharmaceutically acceptable salt thereof to a human who requires treatment for blast phase MPN (MPN-BP). In one embodiment, MPN-BP is selected from the group consisting of blastocystic polycythemia vera (BP-PV), blastocystic myelofibrosis, blastocystic thrombocytopenia, blastocystic essential thrombocytopenia (BP-ET), blastocystic systemic mastocytosis (BP-SM), blastocystic chronic neutrophilic leukemia (BP-CNL), blastocystic myelodysplastic syndrome (BP-MDS), and blastocystic systemic mastocytosis (BP-SMCD). In one embodiment, MPN-BP is selected from the group consisting of blastocystic chronic neutrophilic leukemia (BP-CNL), blastocystic chronic eosinophilic leukemia, blastocystic chronic myelomonocytic leukemia (BP-CMML), blastocystic atypical chronic myeloid leukemia (BP-aCML), blastocystic pediatric myelomonocytic leukemia (BP-JMML), blastocystic hypereosinophilic syndrome (BP-HES), and blastocystic myelodysplastic / myeloproliferative neoplasm with cyclic sideroblasts and thrombocytosis (BP-MDS / MPN-RS-T). In one embodiment, blastocystic polycythemia vera is phlebectomy-dependent polycythemia vera. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is dependent on venotomy. In one embodiment, the human subject does not have splenomegaly and is dependent on venotomy.

[0122] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of reduction in the severity or progression of any myelofibrosis in human subjects receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in human subjects after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt. In one embodiment, the BTK inhibitor is administered to humans according to the dosage and administration regimen in Section 1.

[0123] In one embodiment, MPN is characterized by a CALR mutation.

[0124] In one embodiment, MPN is characterized by an MPL mutation.

[0125] In one embodiment, MPN features the JAK2V617F mutation.

[0126] In one embodiment, MPN features one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR and mixtures thereof.

[0127] Combination with BET inhibitor

[0128] Bromodomain and extraterminal domain (BET) proteins are transcription regulators required for the efficient expression of various growth-promoting, anti-apoptotic genes, and cell cycle progression. The BET family includes BRD2, BRD3, BRD4, and BRDT. During transcription, BET proteins are recruited into chromatin via the N-terminal bromodomain (BRD), where this domain recognizes acetylated lysine residues within histone H3 and H4. Inhibitors of BET disrupt these BET-histone interactions and subsequently downregulate the transcription of oncogenes, including MYC.

[0129] MYC and BTK are important regulators of cellular processes and tumor progression. In light of the relationship between BET inhibition and MYC downregulation, and the relationship between MYC overexpression and cancer, BET inhibitors are useful for treating MYC-associated diseases. Additionally, BET inhibitors combined with BTK inhibitors are useful for treating myeloid cell diseases.

[0130] In some embodiments, the present invention relates to a method for treating splenomegaly, extramedullary hematopoiesis, or fibrosis by administering an effective amount of a BTK inhibitor in combination with a BET inhibitor to a human subject requiring treatment for splenomegaly, extramedullary hematopoiesis, or fibrosis. The disclosure of the present invention demonstrates that a preferred therapeutic agent can be selected based on BTK inhibition and BET inhibition. Thus, although it is not desired to be bound by a specific mechanism of action, BTK inhibition combined with BET inhibition is expected to be useful for mobilizing the migration of CD34+ cells into peripheral blood by altering one or more downstream signaling components (e.g., CXCR-4, CXCL12, VLA-4, VCAM1) and for the treatment or prevention of complications associated with myelofibrosis, particularly one or more complications of myelofibrosis including but not limited to splenomegaly, extramedullary hematopoiesis, or fibrosis.

[0131] Accordingly, the present invention relates to a method for treating splenomegaly, extramedullary hematopoiesis, or fibrosis, comprising the step of administering a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof in combination with a BET inhibitor compound selected from Table 2 or a pharmaceutically acceptable salt thereof to a human requiring treatment for splenomegaly, extramedullary hematopoiesis, or fibrosis. In some embodiments, splenomegaly is secondary to myelofibrosis. In some embodiments, splenomegaly is associated with primary myelofibrosis, also known as chronic idiopathic myelofibrosis. This is in contrast to myelofibrosis occurring secondary to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention encompasses treating splenomegaly caused by myelofibrosis occurring secondary to polycythemia vera or essential thrombocytopenia. In some embodiments, the BTK inhibitor is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof that is combined with a BET inhibitor compound selected from Table 2 or a pharmaceutically acceptable salt thereof. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effects). In one embodiment, the human subject is determined to be hydroxyurea tolerance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent.

[0132] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of a reduction in the severity or progression of any myelofibrosis in a human subject receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in a human subject after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and a pharmaceutically acceptable salt thereof. In one embodiment, the human suffers from splenomegaly, extramedullary hematopoiesis, or fibrosis characterized by one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR, and combinations thereof.

[0133] Table 2: BET inhibitors

[0134]

[0135] The present invention comprises a method for treating myelofibrosis, comprising the step of administering a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof in combination with a BET inhibitor selected from Table 2 or a pharmaceutically acceptable salt thereof to a human requiring treatment for myelofibrosis. In some embodiments, the myelofibrosis is primary myelofibrosis, also known as chronic idiopathic myelofibrosis. This is in contrast to myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention comprises treating myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. In some embodiments, the BTK inhibitor is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof combined with a BET inhibitor compound selected from Table 2 or a pharmaceutically acceptable salt thereof. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to have hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent.

[0136] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of a reduction in the severity or progression of any myelofibrosis in a human subject receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in a human subject after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and a pharmaceutically acceptable salt thereof. In one embodiment, the human suffers from splenomegaly, extramedullary hematopoiesis, or fibrosis characterized by one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR, and combinations thereof.

[0137] In some embodiments, the BET inhibitor is administered once, twice, three times, four times, or five times a day. In some embodiments, the BTK inhibitor is administered at a dose of about 40 mg / day to about 1000 mg / day. In some embodiments, the BTK inhibitor is administered orally. In some embodiments, the BTK inhibitor and the BET inhibitor are administered simultaneously, sequentially, or intermittently.

[0138] The dosage and administration of BET inhibitors are as described herein.

[0139] In some embodiments, the invention comprises pharmaceutical combinations comprising (a) a BTK inhibitor; (b) a BET inhibitor; and (c) pharmaceutically acceptable excipients. In some embodiments, the combination provides a synergistic therapeutic effect compared to the administration of the BTK inhibitor or the BET inhibitor alone. In some embodiments, the combination sensitizes myelofibrosis to the BTK inhibitor. In some embodiments, the BET inhibitor is a compound selected from Table 2 or a pharmaceutically acceptable salt thereof. In some embodiments, the BTK inhibitor is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the combination is a combined dosage form. In some embodiments, the combination is an individual dosage form.

[0140] In some embodiments, the present invention covers the use of a combination comprising a therapeutically effective amount of a BTK inhibitor and a BET inhibitor to treat splenomegaly, extramedullary hematopoiesis, or fibrosis in human subjects requiring treatment for splenomegaly, extramedullary hematopoiesis, or fibrosis. In some embodiments, the combination provides a synergistic therapeutic effect compared to the administration of a BTK inhibitor or a BET inhibitor alone. In some embodiments, the combination sensitizes malignant CD34+ bone marrow cells to the BTK inhibitor. In some embodiments, the BET inhibitor comprises a compound from Table 2 or a pharmaceutically acceptable salt thereof. In some embodiments, splenomegaly, extramedullary hematopoiesis, or fibrosis is associated with primary myelofibrosis, also known as chronic idiopathic myelofibrosis. This is in contrast to myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention covers the treatment of splenomegaly, extramedullary hematopoiesis, or fibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. In one embodiment, myelofibrosis is selected from the group consisting of primary myelofibrosis, secondary myelofibrosis, myelofibrosis secondary to polycythemia vera, myelofibrosis secondary to essential thrombocytopenia, myelofibrosis secondary to chronic myeloid leukemia, and idiopathic myelofibrosis. In one embodiment, myelofibrosis is selected from the group consisting of primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after essential thrombocytopenia. In one embodiment, primary myelofibrosis is selected from the group consisting of prefibrotic / early stage PMF and apparent fibrotic stage PMF. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistance (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is venostole-dependent.In one embodiment, the human subject is splenomegaly-free and venostole-dependent.

[0141] In one embodiment, the human subject is a JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is intolerant to JAK2 inhibitors. In one embodiment, the human subject is ineligible for JAK2 inhibitors due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the recurrence of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of reduction in the severity or progression of any myelofibrosis in human subjects receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in human subjects after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt.

[0142] In some embodiments, the present invention covers the use of a combination comprising a therapeutically effective amount of a BTK inhibitor and a BET inhibitor for treating myelofibrosis, comprising administering the combination comprising a therapeutically effective amount of a BTK inhibitor and a BET inhibitor to a human subject requiring treatment for myelofibrosis. In some embodiments, the combination provides a synergistic therapeutic effect compared to the administration of the BTK inhibitor or the BET inhibitor alone. In some embodiments, the combination sensitizes the myelofibrosis to the BTK inhibitor. In some embodiments, the BET inhibitor is a compound selected from Table 2 or a pharmaceutically acceptable salt thereof. In some embodiments, the BTK inhibitor is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof. In some embodiments, the myelofibrosis is primary myelofibrosis, also known as chronic idiopathic myelofibrosis. This is in contrast to myelofibrosis occurring secondarily to polycythemia vera or essential thrombocytopenia. However, in some embodiments, the present invention covers the treatment of splenomegaly caused by myelofibrosis occurring secondary to polycythemia vera or essential thrombocytopenia. In some embodiments, the BTK inhibitor is a compound selected from Table 1 or a pharmaceutically acceptable salt thereof combined with a compound selected from Table 2 or a pharmaceutically acceptable salt thereof. In one embodiment, the human is determined to be hydroxyurea intolerance (unacceptable side effect). In one embodiment, the human subject is determined to be hydroxyurea resistant (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomizing-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomizing-dependent. In one embodiment, the human subject is JAK2 inhibitor naive (i.e., has never received therapy with a JAK2 inhibitor). In one embodiment, the human subject is JAK2 inhibitor intolerance.In one embodiment, the human subject is ineligible for a JAK2 inhibitor due to a low platelet count. In one embodiment, the human subject relapsed after JAK2 inhibitor treatment. In one embodiment, the human subject is refractory to JAK2 inhibitor treatment. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy. Failure of ruxolitinib or fedratinib therapy includes, but is not limited to, (i) the absence of a reduction in the severity or progression of any MPN in the human subject receiving ruxolitinib or fedratinib, or (ii) the relapse of any myelofibrosis in the human subject after ruxolitinib or fedratinib therapy. In one embodiment, failure of ruxolitinib or fedratinib therapy is the absence of a reduction in the severity or progression of any myelofibrosis in the human subject receiving ruxolitinib or fedratinib. In one embodiment, failure of ruxolitinib or fedratinib therapy is the recurrence of any myelofibrosis in a human subject after ruxolitinib or fedratinib therapy. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and a pharmaceutically acceptable salt thereof. In one embodiment, the human suffers from splenomegaly, extramedullary hematopoiesis, or fibrosis characterized by one or more mutations selected from the group consisting of JAK2V617F, MPL, CALR, and combinations thereof.

[0143] Pharmaceutical composition

[0144] In some embodiments, the present invention provides a pharmaceutical composition comprising a BTK inhibitor compound selected from Table 1 for myelofibrosis or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a pharmaceutical composition comprising a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof for treating myelofibrosis, primary myelofibrosis or idiopathic myelofibrosis. In one embodiment, the myelofibrosis is selected from primary myelofibrosis, myelofibrosis after polycythemia vera, and myelofibrosis after thrombocytopenia.

[0145] In some embodiments, the present invention provides a pharmaceutical composition comprising a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof for treating polycythemia vera, essential thrombocytopenia or myelofibrosis secondary to chronic myeloid leukemia.

[0146] The pharmaceutical composition is typically formulated to provide a therapeutically effective amount of a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical composition contains a pharmaceutically acceptable salt and / or its coordination complex, and one or more pharmaceutically acceptable excipients, carriers such as inert solid diluents and fillers, diluents such as sterile aqueous solutions and various organic solvents, permeability enhancers, solubilizers, and ajuvants. Preferably, other components other than the BTK inhibitor or its pharmaceutically acceptable salt may be mixed into one formulation, or both components may be formulated into individual formulations for use individually or in combination.

[0147] In selected embodiments, the concentration of the BTK inhibitor or its pharmaceutically acceptable salt provided in the pharmaceutical composition of the present invention is, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w / w, w / v, or v / v less than.

[0148] In selected embodiments, the concentration of the BTK inhibitor or its pharmaceutically acceptable salt provided in the pharmaceutical composition of the present invention is independently 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%, 14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% is greater than w / w, w / v, or v / v.

[0149] In selected embodiments, the concentration of the BTK inhibitor or its pharmaceutically acceptable salt is independently about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, and about 0.6%. The range is approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, or approximately 1% to approximately 10% w / w, w / v, or v / v.

[0150] In selected embodiments, the concentration of the BTK inhibitor or its pharmaceutically acceptable salt is independently in the range of approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, and approximately 0.1% to approximately 0.9% w / w, w / v, or v / v.

[0151] In selected embodiments, the amount of BTK inhibitor or its pharmaceutically acceptable salt is independently 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g or less.

[0152] In selected embodiments, the amount of BTK inhibitor or its pharmaceutically acceptable salt is independently 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 It is greater than g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g.

[0153] The BTK inhibitor compounds and their pharmaceutically acceptable salts in Table 1 are effective over a wide range of dosages. For example, in the treatment of adult humans, dosages ranging from 0.01 to 1000 mg, 0.5 to 100 mg, 1 to 50 mg, and 5 to 40 mg per day may be used independently. The exact dosage will depend on the route of administration, the form in which the compound is administered, the sex and age of the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[0154] Non-limiting exemplary pharmaceutical compositions and methods for manufacturing the same are described below.

[0155] Pharmaceutical composition for oral administration

[0156] In a selected embodiment, the present invention provides a pharmaceutical composition for oral administration comprising a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient suitable for oral administration.

[0157] In selected embodiments, the present invention provides a solid pharmaceutical composition for oral administration containing (i) an effective amount of a BTK inhibitor or a pharmaceutically acceptable salt thereof in combination with (ii) a pharmaceutical excipient suitable for oral administration. In selected embodiments, the composition further contains (iii) an effective amount of at least one additional active ingredient.

[0158] In selected embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. The pharmaceutical composition of the present invention suitable for oral administration may exist in individual dosage forms, such as capsules, cases, or tablets, or as a liquid or aerosol spray, solution, or suspension in an aqueous or non-aqueous liquid, oil-in-water emulsion, or water-in-oil emulsion containing a predetermined amount of the active ingredient in powder or granules. These dosage forms may be prepared by any method, but all methods include the step of associating the active ingredient(s) constituting one or more necessary ingredients with a carrier. Generally, the composition is prepared by uniformly and intimately mixing the active ingredient(s) with a liquid carrier or a finely divided solid carrier, or both, and then, if necessary, molding the product into a desired shape. For example, tablets may be prepared by compression and molding with optionally one or more auxiliary ingredients. Compressed tablets may be manufactured by compressing an active ingredient in a free-flowing form, such as powder or granules, mixed with excipients, such as binders, lubricants, inert diluents and / or surfactants or dispersants, optionally in a suitable machine. Molded tablets may be manufactured by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.

[0159] Because water can facilitate the decomposition of some compounds, the present invention also encompasses anhydrous pharmaceutical compositions and dosage forms. For example, water may be added in the pharmaceutical field as a means of simulating long-term storage to determine characteristics such as the shelf-life or stability of a formulation over time (e.g., 5%). The anhydrous pharmaceutical compositions and dosage forms of the present invention may be produced using anhydrous or low-moisture containing ingredients and low-moisture or low-humidity conditions. Pharmaceutical compositions and dosage forms of the present invention containing lactose may be produced anhydrous where substantial contact with moisture and / or humidity is expected during manufacturing, packaging, and / or storage. The anhydrous pharmaceutical composition may be produced and stored to maintain its anhydrous properties. Accordingly, the anhydrous composition may be packaged using materials known to prevent exposure to water so that it can be included in a suitable prescription kit. Examples of suitable packaging include, but are not limited to, completely sealed foil, plastic, etc., unit-dose containers, blister packs, and strip packs.

[0160] BTK inhibitors or their pharmaceutically acceptable salts may be combined with pharmaceutical carriers in an intimate mixture according to conventional pharmaceutical formulation techniques. The carrier may take on a wide variety of forms depending on the form of formulation preferred for administration. In the preparation of a composition for an oral dosage form, any ordinary pharmaceutical medium may be used as a carrier, e.g., water, glycol, oil, alcohol, flavoring agent, preservative, coloring agent, etc., in the case of oral liquid formulations (e.g., suspensions, solutions, and elixirs) or aerosols; or a carrier, e.g., starch, sugar, microcrystalline cellulose, diluent, granulator, lubricant, binder, and disintegrant, may be used without lactose in some embodiments in the case of oral solid formulations. For example, suitable carriers include powders, capsules, and tablets with solid oral formulations. If preferred, tablets may be coated by standard aqueous or non-aqueous techniques.

[0161] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanths, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose), polyvinylpyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

[0162] Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrate, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

[0163] A disintegrant may be used in the composition of the present invention to provide a tablet that disintegrates upon exposure to an aqueous environment. Too much disintegrant may produce a tablet that disintegrates in a vial. Too little may be insufficient for disintegration to occur, thereby altering the rate and extent of release of the active ingredient from the dosage form. Therefore, a dosage form of the compound disclosed herein may be formed using a sufficient amount of disintegrant that is neither too little nor too much, so as not to adversely alter the release of the active ingredient(s). The amount of disintegrant used may vary based on the type of formulation and the method of administration, which can be easily identified by a person skilled in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form the pharmaceutical composition and dosage form of the present invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, sodium croscarmellose, crospovidone, potassium polacrylin, sodium starch glycolate, potato or tapioca starch, other starch, pre-gelatinized starch, other starch, clay, other algin, other cellulose, gum, or mixtures thereof.

[0164] Lubricants that may be used to form the pharmaceutical composition and dosage form of the present invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, or mixtures thereof. Additional lubricants include, for example, siloid silica gel, agglomerated aerosols of synthetic silica, or mixtures thereof. The lubricant may optionally be added in an amount of less than about 1 weight percent of the pharmaceutical composition.

[0165] Where an aqueous suspension and / or elixir is preferred for oral administration, the essential active ingredient therein may be combined with a diluent such as water, ethanol, propylene glycol, glycerin and various combinations thereof, various sweeteners or flavorings, colorings or dyes, and, if preferred, emulsifiers and / or suspending agents.

[0166] The tablet may be uncoated or coated by known technology to delay disintegration and absorption in the gastrointestinal tract and thereby provide sustained action over a long period. For example, a time-delaying agent, such as glyceryl monostearate or glyceryl distearate, may be used. The oral formulation may also be present as a hard gelatin capsule (wherein the active ingredient is mixed with an inert solid diluent, e.g., calcium carbonate, calcium phosphate, or kaolin), or a soft gelatin capsule (wherein the active ingredient is mixed with a water or oil medium, e.g., peanut oil, liquid paraffin, or olive oil).

[0167] Surfactants that can be used to form the pharmaceutical composition and dosage form of the present invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be used, a mixture of lipophilic surfactants may be used, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be used.

[0168] Suitable hydrophilic surfactants generally have an HLB value of at least 10, whereas suitable lipophilic surfactants generally have an HLB value of about 10 or less. The experimental parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance ("HLB" value). Surfactants with lower HLB values ​​are more lipophilic or hydrophobic and thus have greater solubility in oil, whereas surfactants with higher HLB values ​​are more hydrophilic and thus have greater solubility in aqueous solutions. Hydrophilic surfactants are generally considered to be compounds with an HLB value exceeding about 10, as well as anionic, cationic, or zwitterionic compounds to which the HLB scale is generally not applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds with an HLB value of about 10 or less. However, the HLB value of surfactants is merely a generally used approximate guideline that enables the formulation of industrial, pharmaceutical, and cosmetic emulsions.

[0169] Hydrophilic surfactants may be ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides and polypeptides; glyceride derivatives of amino acids, oligopeptides and polypeptides; lecithin and hydrogenated lecithin; lysolecithin and hydrogenated lysolecithin; phospholipids and their derivatives; lysophospholipids and their derivatives; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[0170] Among the groups mentioned above, ionic surfactants include, for example: lecithin, lysolecithin, phospholipids, lysophospholipids and their derivatives; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl actylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[0171] Ionic surfactants include lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactic acid fatty acid esters, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citric acid esters of mono / diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, It may be an ionized form of stearate, lauryl sulfate, terasecyl sulfate, docusate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, and their salts and mixtures.

[0172] Hydrophilic nonionic surfactants include alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers, e.g., polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols, e.g., polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters, e.g., polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters, e.g., polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products with at least one member of the group consisting of polyols and glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, their derivatives and analogs; polyoxyethylated vitamins and their derivatives; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; Polyethylene glycol sorbitan fatty acid esters, and hydrophilic transesterification products with at least one member of the group consisting of polyols and triglycerides, vegetable oils, and hydrogenated vegetable oils, are included but not limited thereto. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or saccharide.

[0173] Other hydrophilic nonionic surfactants are, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 Glyceryl Stearate, PEG-20 Glyceryl Oleate, PEG-30 Glyceryl Oleate, PEG-30 Glyceryl Laurate, PEG-40 Glyceryl Laurate, PEG-40 Palm Kernel Oil, PEG-50 Hydrogenated Castor Oil, PEG-40 Castor Oil, PEG-35 Castor Oil, PEG-60 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-60 Corn Oil, PEG-6 Caprate / Caprylate Glycerides, PEG-8 Caprate / Caprylate Glycerides, Polyglyceryl-10 Laurate, PEG-30 Cholesterol, PEG-25 Phytosterols, PEG-30 Soy Sterols, PEG-20 Trioleate, PEG-40 Sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series,and includes poloxamer.

[0174] Suitable lipophilic surfactants include, by way of example: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acid esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products with at least one member of the group consisting of polyols and glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; fat-soluble vitamins / vitamin derivatives; and mixtures thereof. Within the above group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or preferred lipophilic surfactants are hydrophobic transesterification products with at least one member of the group consisting of polyols, vegetable oils, hydrogenated vegetable oils, and triglycerides.

[0175] In one embodiment, the composition may include a solubilizing agent to ensure excellent solubilization and / or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This may be particularly important for compositions intended for non-oral use, such as injectable compositions. A solubilizing agent may also be added to increase the solubility of hydrophilic drugs and / or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

[0176] Examples of suitable solubilizers are as follows: alcohols and polyols, e.g., ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and its isomers, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrin and cyclodextrin derivatives; ethers of polyethylene glycol having an average molecular weight of about 200 to about 6000, e.g., tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; Amides and other nitrogen-containing compounds, e.g., 2-pyrrolidone, 2-piperidone, ε-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters, e.g., ethyl propionate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, epsilon-caprolactone and its isomers, d-valerolactone and its isomers, b-butyrolactone and its isomers; and other solubilizing agents known in the relevant art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidone, monooctanoin, diethylene glycol monoethyl ether, and water, are included but not limited thereto.

[0177] A mixture of solubilizing agents may also be used. Examples include, but are not limited to, triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizing agents include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol, and propylene glycol.

[0178] The amount of solubilizing agent that may be included is not particularly limited. The amount of solubilizing agent provided may be limited to the bioacceptable amount, which can be easily determined by a person skilled in the art. In some situations, for example, to maximize the concentration of the drug, it may be advantageous to include an excess amount of solubilizing agent that far exceeds the bioacceptable amount; in this case, the excess solubilizing agent is removed using conventional techniques, such as distillation or evaporation, before the composition is administered to a patient. Thus, where a solubilizing agent is present, it may be present in a weight ratio of 10% by weight, 25% by weight, 50% by weight, 100% by weight, or up to about 200% by weight, based on the combined weight of the drug and other excipients. If preferred, very small amounts of solubilizing agent, such as 5%, 2%, 1%, or even less than that, may also be used. Typically, the solubilizing agent may be present in an amount of about 1 weight% to about 100 weight%, more typically about 5 weight% to about 25 weight%.

[0179] The composition may further include one or more pharmaceutically acceptable additives and excipients. These additives and excipients include, but are not limited to, detackifiers, defoamers, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity modifiers, flow modifiers, flavoring agents, coloring agents, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[0180] In addition, acids or bases may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium bicarbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS), etc. Also suitable are bases that are salts of pharmaceutically acceptable acids, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, etc. Salts of polypolyacetic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate, may also be used. If the base is a salt, the cation may be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, and alkaline earth metals. Examples may include, but are not limited to, sodium, potassium, lithium, magnesium, calcium, and ammonium.

[0181] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromide, hydroiodide, sulfuric acid, nitric acid, boric acid, phosphoric acid, etc. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, and uric acid.

[0182] Injectable pharmaceutical composition

[0183] In selected embodiments, the present invention provides an injectable pharmaceutical composition comprising a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient suitable for injection. The components and amounts of the agent in the composition are as described herein.

[0184] Forms in which the composition of the present invention may be incorporated for administration by injection include sesame oil, corn oil, cottonseed oil or peanut oil, as well as aqueous or oil suspensions or emulsions containing elixir, mannitol, dextrose or sterile aqueous solutions and similar pharmaceutical vehicles.

[0185] Aqueous solutions in saline solution are also commonly used for injection. Ethanol, glycerol, propylene glycol and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be used. Suitable fluidity can be maintained by the use of coatings, such as lecithin, for example, maintaining the required particle size in the case of dispersions, and the use of surfactants. Prevention of microbial activity can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.

[0186] A sterile injectable solution is prepared by incorporating the required amount of a BTK inhibitor or its pharmaceutically acceptable salt with various other components listed above into a suitable solvent, and then, if necessary, filtering and sterilizing. Generally, a dispersion is prepared by introducing various sterile active ingredients into a sterile vehicle containing a base dispersion medium and other necessary components belonging to those listed above. In the case of a sterile powder for the preparation of a sterile injectable solution, a particular preferred manufacturing method is vacuum-drying and freeze-drying techniques, which obtain a powder of the active ingredient + any additional preferred ingredient from the corresponding solution that has been previously sterile-filtered.

[0187] Administration of BTK inhibitors or their pharmaceutically acceptable salts or pharmaceutical compositions of these compounds may be carried out by any method that enables delivery to the site of action of the compounds. These methods include oral routes, the duodenal route, parenteral injection (including intravenous, intra-arterial, subcutaneous, intramuscular, intravascular, intraperitoneal, or infusion), local (e.g., transdermal application), rectal administration, local delivery via a catheter or stent, or via inhalation. Combinations of compounds may also be administered into fat or into the spinal canal.

[0188] Exemplary parenteral administration forms include a solution or suspension of the active compound in a sterile aqueous solution, for example, an aqueous propylene glycol or dextrose solution. The administration form may be appropriately buffered if necessary.

[0189] The present invention also provides a kit. The kit contains a BTK inhibitor compound selected from Table 1 or a pharmaceutically acceptable salt thereof, either alone or in combination with a suitable package, and includes written materials that may include instructions for use, a discussion of clinical studies, and a list of side effects. Such kits may also include information, such as scientific literature, package inserts, clinical trial results and / or summaries thereof, which indicate or establish the activity and / or benefits of the composition and / or describe dosage, administration, side effects, drug interactions, or other information useful to healthcare providers. Such information may be based on the results of various studies, such as studies using experimental animals involving in vivo models and studies based on human clinical trials. The kit may additionally contain another active pharmaceutical ingredient. Additional articles for suitable packaging and use (e.g., measuring cups for liquid formulations, foil wrapping to minimize air exposure, etc.) are known in the relevant art and may be included in the kit. The kits described herein may be provided, sold, and / or promoted to healthcare providers, including physicians, nurses, pharmacists, prescribers, etc. The kit may also, in selected embodiments, be sold directly to consumers. In one embodiment, the present invention provides a kit comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of myelofibrosis as described herein.

[0190] Dosage and Administration Therapy

[0191] The amount of BTK inhibitor or its pharmaceutically permissible salt administered will vary depending on the individual being treated, the severity of the disorder or condition, the rate of administration, the batch of the compound, and the judgment of the prescribing physician. However, the effective dose is in the range of about 0.001 to about 100 mg per kg body weight per day, e.g., about 1 to about 35 mg / kg / day, as a single or divided dose. For a 70 kg individual, this would be an amount of about 0.05 to 7 g / day, e.g., about 0.05 to about 2.5 g / day. In some cases, a dose level below the lower limit of the aforementioned range may be more appropriate, whereas in other cases, much higher doses may be used without causing any harmful side effects—e.g., by dividing these higher doses into several smaller doses to be administered over the course of a day.

[0192] In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered as a single dose. Multiple daily doses are also administered, for example, twice daily. Typically, this administration will be oral. However, other routes may be used where appropriate.

[0193] In some embodiments, a BTK inhibitor or its pharmaceutically acceptable salt is administered in multiple doses to treat myelofibrosis. In one embodiment, a BTK inhibitor or its pharmaceutically acceptable salt is administered in multiple doses. In one embodiment, administration may be once, twice, three, or four times a day. In one embodiment, administration may be selected from the group consisting of once a day, twice a day, three times a day, or four times a day, once every other day, once a week, twice a week, three times a week, four times a week, every other week, and monthly. In another embodiment, the BTK inhibitor or its pharmaceutically acceptable salt is administered about once a day to about four times a day. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered once daily, while in other embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered twice daily, and in other embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered three times daily. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered three times a week, including Monday, Wednesday, and Friday.

[0194] Administration of the BTK inhibitor or its pharmaceutically acceptable salt may be continued as long as necessary. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 days or longer. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered for 28, 14, 7, 6, 5, 4, 3, 2, or less than 1 day. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered for about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, or about 56 days. In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered continuously and chronically—for example, for the treatment of chronic effects. In another embodiment, administration of the BTK inhibitor or its pharmaceutically acceptable salt continues for less than about 7 days. In another embodiment, administration continues for about 6, 10, 14, 28 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or more than 1 year. In some embodiments, administration continues for about 1 year, 2 years, 3 years, 4 years, or more than 5 years. In some embodiments, continuous administration is achieved and maintained as long as necessary.

[0195] In some embodiments, the effective dose of a BTK inhibitor or its pharmaceutically acceptable salt is about 1 mg to about 600 mg, about 10 mg to about 500 mg, about 20 mg to about 450 mg, about 25 mg to about 200 mg, about 10 mg to about 200 mg, about 20 mg to about 150 mg, about 30 mg to about 120 mg, about 10 mg to about 90 mg, about 20 mg to about 80 mg, about 30 mg to about 70 mg, about 40 mg to about 60 mg, about 45 mg to about 55 mg, about 48 mg to about 52 mg, about 50 mg to about 150 mg, about 60 mg to about 140 mg, about 70 mg to about 130 mg, about 80 mg to about 120 mg, about 90 mg to about 110 mg, about The range is 95 mg to about 105 mg, about 150 mg to about 250 mg, about 160 mg to about 240 mg, about 170 mg to about 230 mg, about 180 mg to about 220 mg, about 190 mg to about 210 mg, about 195 mg to about 205 mg, or about 198 to about 202 mg. In some embodiments, the effective dose of a BTK inhibitor or its pharmaceutically acceptable salt is about 15 mg, about 25 mg, about 30 mg, about 50 mg, about 50 mg, about 75 mg, about 90 mg, about 100 mg, about 120 mg, about 125 mg, about 150 mg, about 175 mg, about 180 mg, about 200 mg, about 225 mg, about 240 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 360 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 480 mg, or about 500 mg.

[0196] In some embodiments, the effective dose of the BTK inhibitor or its pharmaceutically acceptable salt is 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg.

[0197] In some embodiments, the effective dose of a BTK inhibitor or its pharmaceutically acceptable salt is about 0.01 mg / kg to about 4.3 mg / kg, about 0.15 mg / kg to about 3.6 mg / kg, about 0.3 mg / kg to about 3.2 mg / kg, about 0.35 mg / kg to about 2.85 mg / kg, about 0.15 mg / kg to about 2.85 mg / kg, about 0.3 mg to about 2.15 mg / kg, about 0.45 mg / kg to about 1.7 mg / kg, about 0.15 mg / kg to about 1.3 mg / kg, about 0.3 mg / kg to about 1.15 mg / kg, about 0.45 mg / kg to about 1 mg / kg, about 0.55 mg / kg to about 0.85 mg / kg, about 0.65 mg / kg to about 0.8 mg / kg, about 0.7 mg / kg to about 0.75 mg / kg, about 0.7 mg / kg to about 2.15 mg / kg, about 0.85 mg / kg to about 2 mg / kg, about 1 mg / kg to about 1.85 mg / kg, about 1.15 mg / kg to about 1.7 mg / kg, about 1.3 mg / kg to about 1.6 mg / kg, about 1.35 mg / kg to about 1.5 mg / kg, about 2.15 mg / kg to about 3.6 mg / kg, about 2.3 mg / kg to about 3.4 mg / kg, about 2.4 mg / kg to about 3.3 mg / kg, about 2.6 mg / kg to about 3.15 mg / kg, about 2.7 mg / kg to about 3 mg / kg, about 2.8 mg / kg to about 3 mg / kg, or about 2.85 mg / kg to about The range is 2.95 mg / kg. In some embodiments, the effective dose of the BTK inhibitor or its pharmaceutically acceptable salt is about 0.35 mg / kg, about 0.7 mg / kg, about 1 mg / kg, about 1.4 mg / kg, about 1.8 mg / kg, about 2.1 mg / kg, about 2.5 mg / kg, about 2.85 mg / kg, about 3.2 mg / kg, or about 3.6 mg / kg.

[0198] In some embodiments, a BTK inhibitor or its pharmaceutically acceptable salt is administered in doses of 10 to 500 mg BID, e.g., 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg BID.

[0199] In some embodiments, a BTK inhibitor or its pharmaceutically acceptable salt is administered in doses of 10 to 600 mg QD, e.g., 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg QD.

[0200] An effective amount of a BTK inhibitor or its pharmaceutically acceptable salt may be administered as a single or multiple doses by any of the permitted modes of administration of agents of similar utility, including the buccal, sublingual, and transdermal routes, by intra-arterial injection, intravenously, parenterally, intramuscularly, subcutaneously, or orally.

[0201] In some embodiments, the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject intermittently as is known as intermittent administration. “Intermittent administration” means a period of administration of a therapeutically effective dose of the BTK inhibitor or its pharmaceutically acceptable salt, followed by a period of discontinuation, followed by another period of administration, etc. In each period of administration, the frequency of administration may be independently selected from three times daily, twice daily, daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, six times weekly, or monthly. In one embodiment, the BTK inhibitor is a compound or its pharmaceutically acceptable salt selected from Table 1.

[0202] "Discontinuation period" or "halt period" refers to the length of time when administration of a BTK inhibitor or its pharmaceutically acceptable salt is discontinued. The discontinuation period may be longer, shorter, or equal to the administration period. During the discontinuation period, a therapeutic agent other than the BTK inhibitor or its pharmaceutically acceptable salt may be administered. The discontinuation period may be necessary to alleviate any toxic effects associated with a specific BTK inhibitor compound.

[0203] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject requiring treatment for myelofibrosis during a first administration period, followed by a discontinuation period, followed by a second administration period, and so on. The first administration period, the second administration period, and the discontinuation period are independently selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and days exceeding therefrom, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject three times daily, twice daily, once daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, and weekly It is administered six times or monthly. In one embodiment, the first administration period is the same length as the second administration period. In one embodiment, the first administration period is shorter than the second administration period. In one embodiment, the first administration period is longer than the second administration period. In one embodiment, the first administration period and the second administration period are about 1 week, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks.In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; and the discontinuation period is about 2 weeks. In one embodiment, the BTK inhibitor is a compound selected from Table 1 or its pharmaceutically acceptable salt.

[0204] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject requiring treatment for myelofibrosis secondary to polycythemia vera during a first administration period, followed by a discontinuation period, followed by a second administration period, etc. The first administration period, the second administration period, and the discontinuation period are independently selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and days exceeding therefrom, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject three times daily, twice daily, once daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, and weekly It is administered six times or monthly. In one embodiment, the first administration period is the same length as the second administration period. In one embodiment, the first administration period is shorter than the second administration period. In one embodiment, the first administration period is longer than the second administration period. In one embodiment, the first administration period and the second administration period are about 1 week, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks.In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; and the discontinuation period is about 2 weeks. In one embodiment, the BTK inhibitor is a compound selected from Table 1 and its pharmaceutically acceptable salt.

[0205] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject requiring treatment for myelofibrosis secondary to essential thrombocytopenia during a first administration period, followed by a discontinuation period, followed by a second administration period, etc. The first administration period, the second administration period, and the discontinuation period are independently selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and days exceeding therefrom, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject three times daily, twice daily, once daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, and weekly It is administered six times or monthly. In one embodiment, the first administration period is the same length as the second administration period. In one embodiment, the first administration period is shorter than the second administration period. In one embodiment, the first administration period is longer than the second administration period. In one embodiment, the first administration period and the second administration period are about 1 week, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks.In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; and the discontinuation period is about 2 weeks. In one embodiment, the BTK inhibitor is a compound selected from Table 1 or its pharmaceutically acceptable salt.

[0206] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject requiring treatment for myelofibrosis secondary to chronic myeloid leukemia during a first administration period, followed by a discontinuation period, followed by a second administration period, etc. The first administration period, the second administration period, and the discontinuation period are independently selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and days exceeding therefrom, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject three times daily, twice daily, once daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, and weekly It is administered six times or monthly. In one embodiment, the first administration period is the same length as the second administration period. In one embodiment, the first administration period is shorter than the second administration period. In one embodiment, the first administration period is longer than the second administration period. In one embodiment, the first administration period and the second administration period are about 1 week, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks.In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; and the discontinuation period is about 2 weeks. In one embodiment, the BTK inhibitor is a compound selected from Table 1 or its pharmaceutically acceptable salt.

[0207] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject requiring treatment for primary myelofibrosis during a first administration period, followed by a discontinuation period, followed by a second administration period, etc. The first administration period, the second administration period, and the discontinuation period are independently selected from a group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and days exceeding therefrom, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject three times daily, twice daily, once daily, once weekly, twice weekly, three times weekly, four times weekly, five times weekly, and weekly It is administered six times or monthly. In one embodiment, the first administration period is the same length as the second administration period. In one embodiment, the first administration period is shorter than the second administration period. In one embodiment, the first administration period is longer than the second administration period. In one embodiment, the first administration period and the second administration period are about 1 week, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 3 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; the discontinuation period is about 2 weeks. In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject daily; the discontinuation period is about 2 weeks.In one embodiment, the first administration period and the second administration period are about 4 weeks, wherein the BTK inhibitor or its pharmaceutically acceptable salt is administered to the subject weekly; and the discontinuation period is about 2 weeks. In one embodiment, the BTK inhibitor is a compound selected from Table 1 or its pharmaceutically acceptable salt.

[0208] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a subject requiring it to treat myelofibrosis for 3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks, 21 weeks, 24 weeks, 27 weeks, 30 weeks, 33 weeks, 36 weeks, 39 weeks, 42 weeks, 45 weeks, 48 ​​weeks, 51 weeks, 54 weeks, 57 weeks, 60 weeks, 63 weeks, 66 weeks, 69 weeks, 72 weeks, 75 weeks, 78 weeks, 81 weeks, 84 weeks, 87 weeks, 90 weeks, 93 weeks, 96 weeks, 99 weeks, 102 weeks, 105 weeks, 108 weeks, 111 weeks, 114 weeks, 117 weeks, 120 weeks, 123 weeks, 126 weeks, It is administered for a period selected from 129, 132, 135, 138, 141, 144, 147, 150, 153, and 156 weeks, wherein the BTK inhibitor is selected from any of the compounds of Table 1 or their pharmaceutically acceptable salts. In one embodiment, the BTK inhibitor is administered orally at a dose of 100 mg twice daily.

[0209] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a subject requiring it to treat primary myelofibrosis for 3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks, 21 weeks, 24 weeks, 27 weeks, 30 weeks, 33 weeks, 36 weeks, 39 weeks, 42 weeks, 45 weeks, 48 ​​weeks, 51 weeks, 54 weeks, 57 weeks, 60 weeks, 63 weeks, 66 weeks, 69 weeks, 72 weeks, 75 weeks, 78 weeks, 81 weeks, 84 weeks, 87 weeks, 90 weeks, 93 weeks, 96 weeks, 99 weeks, 102 weeks, 105 weeks, 108 weeks, 111 weeks, 114 weeks, 117 weeks, 120 weeks, 123 weeks, 126 weeks, It is administered for a period selected from 129, 132, 135, 138, 141, 144, 147, 150, 153, and 156 weeks, wherein the BTK inhibitor is selected from any of the compounds in Table 1 or their pharmaceutically acceptable salts. In one embodiment, the human subject is hydroxyurea resistant (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy.

[0210] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a subject requiring it to treat myelofibrosis secondary to polycythemia vera for 3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks, 21 weeks, 24 weeks, 27 weeks, 30 weeks, 33 weeks, 36 weeks, 39 weeks, 42 weeks, 45 weeks, 48 ​​weeks, 51 weeks, 54 weeks, 57 weeks, 60 weeks, 63 weeks, 66 weeks, 69 weeks, 72 weeks, 75 weeks, 78 weeks, 81 weeks, 84 weeks, 87 weeks, 90 weeks, 93 weeks, 96 weeks, 99 weeks, 102 weeks, 105 weeks, 108 weeks, 111 weeks, 114 weeks, 117 weeks, 120 weeks, It is administered for a period selected from 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, and 156 weeks, wherein the BTK inhibitor compound is selected from Table 1 and its pharmaceutically acceptable salts.

[0211] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a subject requiring it to treat myelofibrosis secondary to essential thrombocytopenia for 3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks, 21 weeks, 24 weeks, 27 weeks, 30 weeks, 33 weeks, 36 weeks, 39 weeks, 42 weeks, 45 weeks, 48 ​​weeks, 51 weeks, 54 weeks, 57 weeks, 60 weeks, 63 weeks, 66 weeks, 69 weeks, 72 weeks, 75 weeks, 78 weeks, 81 weeks, 84 weeks, 87 weeks, 90 weeks, 93 weeks, 96 weeks, 99 weeks, 102 weeks, 105 weeks, 108 weeks, 111 weeks, 114 weeks, 117 weeks, 120 weeks, It is administered for a period selected from 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, and 156 weeks, wherein the BTK inhibitor compound is selected from Table 1 and its pharmaceutically acceptable salts.

[0212] In one embodiment, a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a subject requiring it to treat myelofibrosis secondary to chronic myeloid leukemia for 3 weeks, 6 weeks, 9 weeks, 12 weeks, 15 weeks, 18 weeks, 21 weeks, 24 weeks, 27 weeks, 30 weeks, 33 weeks, 36 weeks, 39 weeks, 42 weeks, 45 weeks, 48 ​​weeks, 51 weeks, 54 weeks, 57 weeks, 60 weeks, 63 weeks, 66 weeks, 69 weeks, 72 weeks, 75 weeks, 78 weeks, 81 weeks, 84 weeks, 87 weeks, 90 weeks, 93 weeks, 96 weeks, 99 weeks, 102 weeks, 105 weeks, 108 weeks, 111 weeks, 114 weeks, 117 weeks, 120 weeks, It is administered for a period selected from 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, and 156 weeks, wherein the BTK inhibitor compound is selected from Table 1 and its pharmaceutically acceptable salts.

[0213] In some embodiments, the human subject is hydroxyurea resistant (inappropriate response). In one embodiment, the human subject has splenomegaly. In one embodiment, the human subject has splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject does not have splenomegaly and is phlebotomy-dependent. In one embodiment, the human subject failed ruxolitinib or fedratinib therapy.

[0214] Examples

[0215] Embodiments incorporated herein are now described with reference to the following examples. These examples are provided merely for illustrative purposes, and the disclosures incorporated herein should by no means be construed as being limited to these examples, but rather should be construed as encompassing any and all variations that become apparent as a result of the teachings provided herein.

[0216] Example 1: BTK inhibitor monotherapy for a patient with myelofibrosis

[0217] The purpose of this study is to investigate the safety and efficacy of BTK inhibitor compounds in patients with myelofibrosis. Thirty MF patients will be enrolled in the study and will receive 200 or 300 mg of a BTK inhibitor compound once daily. Inclusion criteria are (1) not previously treated with at least one other agent (hydroxyurea, interferon, anagrelide), (2) ≥ 18 years of age, (3) acceptable prior-study institution function during screening as defined below: total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the ULN, serum creatinine ≤ 1.5 x ULN, unless due to Gilbert's disease or hemolysis, and (3) women and men of childbearing age must agree to use appropriate contraception (i.e., hormonal or barrier contraception for pregnancy control; abstinence from alcohol) before entering the study and during the study participation period. If a female subject becomes pregnant or is suspected of being pregnant while participating in this study, she must be immediately excluded from the study.

[0218] During or at the end of the study, each MF patient will be evaluated by the following items to determine the safety and efficacy of the BTK inhibitor compound: (1) blood response; (2) reduction in JAK2V617F allele burden; (3) changes in bone marrow histopathological abnormalities; (4) reduction in baseline reticulin / collagen fibrosis; (5) incidence of venous and arterial thrombosis; and (5) changes in MF-related symptoms.

[0219] Example 2: Open-label, Phase 2a / 2b study of BTK inhibitor compounds

[0220] There is a significant unmet need for improved therapy in patients with myelofibrosis who have primary resistance to ruxolitinib, a suboptimal response, or relapsed after treatment with ruxolitinib. BTK inhibitor compounds are orally bioavailable small molecule cytotoxic chemotherapy agents that bind to BTK.

[0221] Research Design

[0222] This is an open-label, two-part (Part A and Part B), Phase 2a / 2b study of the compound of Formula (I) in subjects of PMF, post-PV-MF, or post-ET-MF who failed ruxolitinib therapy. Approximately 190 subjects will be enrolled in the study (90 in Part A and 100 in Part B).

[0223] Part A (N=90): In Part A of the study, subjects will be randomized to one of the following three treatment groups: Cohort 1, N=30 subjects: 280 mg of a BTK inhibitor compound once daily. Cohort 2, N=30 subjects: 420 mg of a BTK inhibitor compound once daily. Cohort 3, N=30 subjects: 560 mg of a BTK inhibitor compound once daily.

[0224] Part B (N=100): Approximately 100 subjects will be enrolled in Part B and treated with the recommended dosage and schedule from Part A. A Data Monitoring Committee (DMC) will be convened every three months for both Part A and Part B during the course of the study to review safety data for the clinical study. The DMC will also be convened after all subjects in Part A have had the opportunity to complete the 24-week evaluation. Based on the efficacy and safety data from Part A, the DMC will determine the recommended dosage and schedule for the BTK inhibitor compound. In both Part A and Part B, subjects will receive the BTK inhibitor compound orally (PO) once daily on a 28-day cycle. Dose reduction will be permitted for hematological and non-hematological toxicities. All subjects must be treated until disease progression or intolerance occurs. The definition of disease progression is based on imaging and modified ELN criteria: an increase in splenic volume of ≥25% from the lowest point during the study by MRI (or CT) with central agency imaging review, ≥1X10⁻¹⁰ persisting for at least 2 weeks. 9 Leukemia transformation identified by a bone marrow blast cell count of ≥20% or a peripheral blood blast cell content of ≥20% in association with an absolute blast cell count of / L.

[0225] Research purpose

[0226]

[0227] Inclusion criteria

[0228] Subjects in both Part A and Part B must meet all of the following criteria to be eligible for the study: 1. Adult >18 years; 2. Palpable splenomegaly of at least 5 cm below the left costal margin; 3. Confirmed diagnosis of PMF, post-PV-MF, or post-ET-MF upon evaluation by the treating physician according to World Health Organization (WFIO) criteria; 4. High risk, intermediate-2 risk, or intermediate-1 risk as defined by the Dynamic International Prognostic System (DIPSS); 5. ECOG performance status of 0 to 2; 6. Adequate hematological, hepatic, and renal function (within 14 days prior to the first dose of the BTK inhibitor compound as defined in the protocol); Hematological: ANC ≥1.0 x 10 9 / L (in the absence of growth factors for the prior 7 days); platelet count ≥100 x 10 9 / L; peripheral blood blast count <10%. Liver: Total bilirubin ≤ 2.0 times the upper limit of normal (ULN) unless Gilbert's syndrome; aspartate transaminase / serum glutamate oxaloacetate transaminase (AST / SGOT) and alanine transaminase / serum glutamate pyruvate transaminase (ALT / SGPT) ≤ 2.5 ULN · Kidney: Estimated creatinine clearance >45 mL / min according to Cockcroft-Gault below:

[0229]

[0230] 7. Women of childbearing age and men with fertile partners must agree to use effective contraception during the study. Additionally, men must continue contraception for 3 months after the last dose of the study drug, and women must continue contraception for 1 week after the last dose of the study drug. Effective pregnancy control includes (a) combined, estrogen and progestogen-containing, hormonal contraception (oral, vaginal, transdermal); (b) progestogen-only hormonal contraception (oral, injectable, implantable); (c) intrauterine devices; (d) intrauterine hormone-releasing systems; (e) bilateral tubal closure; (f) vasectomy of the partner; and (g) sexual abstinence.

[0231] Subjects in Part A must meet the following criteria for failure of ruxolitinib treatment to be eligible for the study: Failure of ruxolitinib treatment in Part A must meet either criterion (a) or (b) below: (a) receiving at least 12 weeks of ruxolitinib treatment and having both of the following: persistent splenomegaly on physical examination, i.e., palpable splenomegaly ≥ 5 cm below the lower costal margin (LCM), and a patient with a TSS of > 10 for MPN-SAF TSS 2.0 or a single symptom score of > 5, including only symptoms of left upper quadrant pain, bone pain, pruritus, or night sweats, or two symptoms of > 3; or (b) progressive disease at any point during ruxolitinib treatment as defined by either of the following: an increase in splenic volume by ≥ 25% from the trough when assessed by MRI or CT, or the appearance of new palpable splenomegaly at least 5 cm below the LCM. For baseline splenomegaly of 5 to 10 cm, increase in palpable distance below LCM by ≥ 100%, and for baseline splenomegaly of > 10 cm, increase in palpable distance below LCM by ≥ 50%.

[0232] Subjects in Part B must meet the following criteria for failure of ruxolitinib treatment to be eligible for the study: Failure of ruxolitinib treatment in Part B must meet either criterion (a) or (b) below: (a) Lack of a splenic response defined as having at least one of the following, received for at least 12 weeks of ruxolitinib treatment: for subjects undergoing MRI or CT to evaluate ruxolitinib treatment, failure to reduce splenic volume by at least ≥ 35%; retention of palpable baseline splenomegaly pre-ruxolitinib treatment 5 to 10 cm below the LCM as palpable; failure of palpable baseline splenomegaly pre-ruxolitinib treatment or (b) progressive disease at any point in time during ruxolitinib treatment as defined by any of the following: ≥ 25% increase in splenic volume from the lowest point when evaluated by MRI or CT, appearance of a new palpable splenomegaly at least 5 cm below the LCM, ≥ 100% increase in baseline splenomegaly at a palpable distance below the LCM, or ≥ 50% increase in baseline splenomegaly at a palpable distance below the LCM at > 10 cm.

[0233] Exclusion criteria

[0234] Subjects in both Part A and Part B who meet any of the following criteria will not be eligible for the study: 1. Participation in another intervention clinical trial within the past 4 weeks of the first dose of the compound of Formula (I) (participation in observational studies is permitted). 2. Recent / combination therapy within 4 weeks or approximately 5 half-lives of the first dose of the compound of Formula (I), e.g., major surgery, chemotherapy, immunomodulatory therapy, biological therapy, radiotherapy, or irradiation therapy. 3. Prior splenectomy. 4. Splenic irradiation within 3 months prior to the first dose of the compound of Formula (I). 5. Prior allogeneic stem cell transplantation or eligibility for allogeneic stem cell transplantation. 6. Prior treatment with histone deacetylase (HDAC) inhibitors or BCL-2 inhibitors. 7. Prior BTK inhibitor therapy. 8. Pregnant or breastfeeding women. 9. History of major organ transplantation. 10. Acute hepatitis A; A known history of human immunodeficiency virus (HIV) positivity; clinically significant heart disease (NYC Heart Class III or IV); symptomatic congestive heart failure; unstable angina ventricular arrhythmia; or uncontrolled concomitant disease including, but not limited to, psychotic / social conditions that limit compliance with study requirements. 11. Subjects with clinically significant bacterial, fungal, parasitic, or viral infections requiring therapy. Screening / enrollment for subjects with acute bacterial infections requiring antibiotic use should be delayed until the course of antibiotic therapy is completed. Other malignancies within the last 3 years, excluding curatively treated basal cell or squamous cell skin cancer, cervical intraepithelial carcinoma, organ-limiting or cured non-metastatic prostate cancer with normal prostate-specific antigens, breast intraepithelial carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma. 13. Grade 2 or higher QTc extension (>480 milliseconds / NCI-CTCAE standard, version 5.0). 14.Hematopoietic growth factors (i.e., erythropoietin (Epo), granulocyte colony-stimulating factor (GCSF), romiplostim) within 28 days prior to receiving the first dose of the compound of formula (I). 15. Active or chronic bleeding within 4 weeks prior to the first dose of the compound of formula (I).

[0235] Randomization procedure

[0236] Part A: Subjects will be randomized into one of three treatment cohorts under a 1:1:1 allocation plan. The contracted clinical service provider will develop the Part A randomization schedule, and actual randomization allocation will be performed via a Secure Interaction Response Technology (IRT) system. Part B: Subjects will be randomized to BTK inhibitor compound doses and schedules recommended by the DMC.

[0237] Statistical analysis

[0238] To review safety data for the clinical study, the DMC will be convened every three months for Part A and Part B during the course of the study. The DMC will also be convened after all subjects in Part A have had the opportunity to complete the 24-week evaluation. Based on the efficacy and safety data from Part A, the DMC will determine the recommended dosage and schedule for the BTK inhibitor compound for Part B. Results of statistical analysis, technical summary statistics, and supporting lists will be presented by study part (A or B) and within Part A (by cohort).

[0239] Research period

[0240] The study will be considered completed two years after the last subject is enrolled, at which time subjects who have maintained the study treatment will be evaluated for eligibility to enroll in the rollover study.

[0241] Example 3: BTK inhibition in healthy B-cells and bone marrow cells

[0242] The inhibition of BTK phosphorylation (activation) by compound number 128 (1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidine-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one) was evaluated in healthy B-cells and bone marrow cell lines MOLM-13 and Hel-92. Compound number 128 was incubated with bone marrow cell lines for 2 hours without stimulation, and with healthy PBMCs for 2 hours with 10 minutes of αIgM and H2O2 stimulation. As shown in Table 3, the effect of compound 128 on bone marrow cells was similar to its effect on healthy B-cells.

[0243] Table 3: BTK inhibition

[0244]

[0245] Example 4: Inhibition of cell migration to SDF-1 (CXCL12)

[0246] In MF, the spleen has high levels of SDF-1 compared to blood. The chemokine SDF-1 attracts cells along a concentration gradient. In vitro inhibition of cell migration across a permeable membrane by compound no. 128 and ruxolitinib (Rux) was evaluated using Hel-92 (V617F mut) cells. As shown in Figures 1a and 1b, both compound no. 128 and ruxolitinib inhibit cell migration to SDF-1.

[0247] Example 5: Fibronectin release

[0248] Fibronectin is an important component of the extracellular matrix of the microenvironment and attaches to cells via VLA-4 (integrin α4β1). 1x10 6The detachment of MV-411 cells from fibronectin after exposure to Compound No. 128 was evaluated by plating the cells onto fibronectin-coated plates (repeated three times). Cells were allowed to adhere overnight at 37°C, after which unattached cells were washed. The attached cells were then treated with DMSO or Compound 128 (1, 2, or 5 pm) at 37°C for 2 hours. The detached cells were then collected, and the cell count was determined using CellTiter Glo. As shown in Figure 2, cells were detached from fibronectin after exposure to Compound No. 128.

[0249] Example 6: Expression of surface molecules involved in cell adhesion

[0250] Reducing the expression of surface molecules involved in the attachment of cells to their microenvironment can inhibit the protection of malignant cells in various ways. Monocytes from the blood of COVID-19 patients treated with compound number 128 were evaluated for the levels of surface molecules CD11a (LFA-1), CD62L (L-selectin), and CD49d (VLA-4). As shown in Figure 3, treatment with compound 128 reduced the levels of surface molecules in some patients.

[0251] Example 7: Cytokine production

[0252] The effect on in vitro cytokine production after exposure to compound number 128 was evaluated in stimulated whole blood after 24 hours of incubation. As shown in Figure 4, compound number 128 reduced cytokine and chemokine production upon cell stimulation.

Claims

Claim 1 Use of Bruton's tyrosine kinase (BTK) inhibitors for the treatment of myelofibrosis in human subjects.